Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.
VTE risk up with chemotherapy, radiation therapy; major bleeding risk up with PE, proximal DVT.
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
A study suggested that the immunotherapy could be sensitizing non-Hodgkin lymphoma patients to subsequent therapies.
The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.
Researchers presented findings of a significantly higher 5-year OS rate in patients who received 4 cycles of eBEACOPP compared with patients who received 6/8 cycles.
Administering MD-MTX prophylaxis against CNS relapse of DLBCL appeared best as early as possible or following R-CHOP completion.
Modifications of ABVD or CHOP were common among elderly patients with cHL and may contribute to their disproportionate excess mortality, signaling a need for less toxic regimens.
Inotuzumab ozogamicin instead of gemcitabine added to R-CVP did not improve OS or PFS, but less toxicity among patients with untreated DLBCL with comorbid conditions.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Researchers conducted a multicenter, retrospective analysis of outcomes for 1360 patients who were treated with RT with or without nonanthracycline-based CT.
Dose-adjusted EPOCH-R resulted in higher tolerance and efficacy among adults with Burkitt lymphoma.
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Obinutuzumab plus chemotherapy showed more durable efficacy, safety, and longer progression-free survival for patients with untreated follicular lymphoma.
Using data from 108 patients, researchers designed MIPI-P, a novel scoring system for determining MCL prognosis.
Researchers reported long-term follow up from the first clinical trial of anti-CD19 CAR T cells that revealed responses against lymphoma.
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Pembrolizumab showed statistically significant improvement in PFS compared with brentuximab vedotin in patients with r/r cHL.